

IDRAC[®] CHINA MODULE

A SINGLE, AUTHORITATIVE SOURCE OF CHINESE REGULATORY REQUIREMENTS



WHAT SETS IDRAC APART?

- An unrivaled depth of global information
- Covers both established and emerging economies
- Unique, proprietary regulatory intelligence
- Compiled by Thomson Reuters regulatory experts
- Every entry is curated manually

HOW YOU CAN BENEFIT

- Optimize your regulatory strategy and minimize your risk
- Save time and cost
- Get your product to the market on time and keep it there
- Gain a competitive advantage

UNSURPASSED DEPTH OF COVERAGE

The China module contains 49 explanatory documents, written by a local expert and based on *IDRAC* proprietary specifications, covering:

- The organization and function of authorities, the State Food and Drug Administration (SFDA), and the Ministry of Health (MOH)
- What is regulated by the China Drug Administration Law
- The types of business licenses and applications required for registration of medicinal products in China
- The data required in the Chinese approval application for clinical trials and registration
- The step-by-step review procedure of Chinese clinical trials and approval, as well as marketing authorization approval
- How medicinal products are advertised and promoted in China
- Fees, pricing, and reimbursement
- Wholesale and marketing medicinal products in China
- How Chinese guidelines including GMP, GLP, GCP, GRP, and GSP are regulated
- The Chinese ADR monitoring and reporting system

In addition, the China module includes English translations of official regulatory documents, including:

- The China Drug Administration Law
- Regulations for Implementation of Drug Administration Law
- Chinese Good Manufacturing Practice
- Chinese Good Clinical Practice
- SFDA Orders (Technical Guideline for Pharmaceuticals)

REQUEST A TRIAL

Contact us today to take an IDRAC trial and see for yourself how it will improve your regulatory affairs intelligence. Contact us at scientific.thomsonreuters.com/contact

